Flavio Crippa

4.5k total citations
124 papers, 3.2k citations indexed

About

Flavio Crippa is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Flavio Crippa has authored 124 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Radiology, Nuclear Medicine and Imaging, 44 papers in Oncology and 43 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Flavio Crippa's work include Medical Imaging Techniques and Applications (32 papers), Radiopharmaceutical Chemistry and Applications (25 papers) and Sarcoma Diagnosis and Treatment (18 papers). Flavio Crippa is often cited by papers focused on Medical Imaging Techniques and Applications (32 papers), Radiopharmaceutical Chemistry and Applications (25 papers) and Sarcoma Diagnosis and Treatment (18 papers). Flavio Crippa collaborates with scholars based in Italy, United States and Japan. Flavio Crippa's co-authors include Emilio Bombardieri, A. Bogni, Claudio Pascali, Ettore Seregni, Flavio Villani, Silvia Stacchiotti, Paolo G. Casali, Gianni Bonadonna, Alessandro Gronchi and Luigi Mariani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Flavio Crippa

122 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Flavio Crippa Italy 30 1.1k 1.1k 962 729 609 124 3.2k
Carlo Spreafico Italy 26 1.3k 1.2× 1.2k 1.1× 370 0.4× 762 1.0× 292 0.5× 79 3.6k
Yoshiki Mikami Japan 41 1.1k 1.0× 921 0.8× 573 0.6× 1.5k 2.0× 523 0.9× 231 5.3k
Chang‐Ok Suh South Korea 38 1.3k 1.1× 1.6k 1.5× 582 0.6× 1.2k 1.6× 1.3k 2.2× 250 4.8k
Weining Zhen United States 22 932 0.9× 562 0.5× 482 0.5× 892 1.2× 168 0.3× 67 2.7k
Mercè Jordà United States 33 1.3k 1.2× 1.0k 0.9× 278 0.3× 977 1.3× 264 0.4× 157 3.2k
Christina Messiou United Kingdom 36 2.5k 2.3× 2.1k 1.9× 1.7k 1.7× 597 0.8× 450 0.7× 180 5.8k
Robert A. Lefkowitz United States 28 1.8k 1.6× 1.0k 0.9× 638 0.7× 494 0.7× 203 0.3× 68 2.8k
Rick L. Haas Netherlands 33 2.5k 2.3× 1.5k 1.4× 309 0.3× 525 0.7× 601 1.0× 114 3.4k
Noah Federman United States 28 1.3k 1.2× 1.0k 0.9× 220 0.2× 295 0.4× 334 0.5× 142 3.0k
Malcolm Hayes Canada 27 626 0.6× 1.4k 1.3× 332 0.3× 428 0.6× 943 1.5× 92 3.2k

Countries citing papers authored by Flavio Crippa

Since Specialization
Citations

This map shows the geographic impact of Flavio Crippa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavio Crippa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavio Crippa more than expected).

Fields of papers citing papers by Flavio Crippa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Flavio Crippa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavio Crippa. The network helps show where Flavio Crippa may publish in the future.

Co-authorship network of co-authors of Flavio Crippa

This figure shows the co-authorship network connecting the top 25 collaborators of Flavio Crippa. A scholar is included among the top collaborators of Flavio Crippa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flavio Crippa. Flavio Crippa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alessi, Alessandra, Alice Lorenzoni, Anna Cavallo, et al.. (2018). Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. La radiologia medica. 124(5). 414–421. 16 indexed citations
2.
Necchi, Andrea, Salvatore Lo Vullo, Patrizia Giannatempo, et al.. (2017). Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Annals of Oncology. 28(6). 1346–1351. 31 indexed citations
3.
Guidetti, Anna, Arabella Mazzocchi, Rosalba Miceli, et al.. (2017). Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leukemia Research. 62. 91–97. 13 indexed citations
4.
Necchi, Andrea, Domenico Magazzù, Andrea Anichini, et al.. (2016). An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).. Journal of Clinical Oncology. 34(2_suppl). 480–480. 15 indexed citations
5.
Maccauro, Marco, Alice Lorenzoni, Flavio Crippa, et al.. (2016). Sentinel Lymph Node Biopsy in Pelvic Tumors. Clinical Nuclear Medicine. 41(6). e288–e293. 6 indexed citations
6.
Tazzari, Marcella, Elena Palassini, Barbara Vergani, et al.. (2015). Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer. 15(1). 58–58. 17 indexed citations
7.
Necchi, Andrea, Patrizia Giannatempo, Luigi Mariani, et al.. (2014). PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Investigational New Drugs. 32(3). 555–560. 49 indexed citations
8.
Stacchiotti, Silvia, Flavio Crippa, A. Messina, et al.. (2013). Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. PubMed. 3(1). 8–8. 36 indexed citations
9.
Necchi, Andrea, Nadia Zaffaroni, Luigi Mariani, et al.. (2012). Abstract LB-433: Biomarker analysis and final results of INT70/09 Phase II proof-of-concept study of Pazopanib (PZP) in refractory urothelial cancer (UC). Cancer Research. 72(8_Supplement). LB–433. 1 indexed citations
10.
Necchi, Andrea, Nicola Nicolai, Claudia Ortega, et al.. (2011). Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC).. Journal of Clinical Oncology. 29(15_suppl). 4618–4618. 5 indexed citations
11.
Casali, Paolo G., Silvia Stacchiotti, Federica Grosso, et al.. (2007). Adding cisplatin (CDDP) to imatinib (IM) re-establishes tumor response following secondary resistance to IM in advanced chordoma. Journal of Clinical Oncology. 25(18_suppl). 10038–10038. 19 indexed citations
12.
13.
Licitra, Lisa, Laura D. Locati, Paolo Potepan, et al.. (2006). Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional phase II study. Journal of Clinical Oncology. 24(18_suppl). 5547–5547. 15 indexed citations
14.
Damascelli, B, Gianluigi Patelli, Rodolfo Lanocita, et al.. (2003). A Novel Intraarterial Chemotherapy Using Paclitaxel in Albumin Nanoparticles to Treat Advanced Squamous Cell Carcinoma of the Tongue: Preliminary Findings. American Journal of Roentgenology. 181(1). 253–260. 53 indexed citations
15.
Crippa, Flavio, Raffaele Bruno, Enrico Brunetti, & Carlo Fìlice. (1999). Echinococcal liver cysts: treatment with echo-guided percutaneous puncture PAIR for echinococcal liver cysts.. PubMed. 31(9). 884–92. 19 indexed citations
16.
Bozzetti, Federico, Cecilia Gavazzi, Luigi Mariani, & Flavio Crippa. (1999). Artificial Nutrition in Cancer Patients: Which Route, What Composition?. World Journal of Surgery. 23(6). 577–583. 21 indexed citations
17.
Crippa, Flavio, et al.. (1990). Clinical Value of Radioimmunoscintigraphy in the follow-up of Ovarian Carcinoma: A Prospective Study. The International Journal of Biological Markers. 5(3). 103–108. 3 indexed citations
18.
Villani, Fabrizio, et al.. (1989). Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). European Journal of Cancer and Clinical Oncology. 25(1). 13–18. 22 indexed citations
19.
Villani, Flavio, et al.. (1988). Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.. PubMed. 26(4). 185–9. 2 indexed citations
20.
Villani, Flavio, et al.. (1985). Preliminary evaluation of myocardial toxicity of 4'-deoxydoxorubicin: experimental and clinical results.. PubMed. 11(3). 223–31. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlo Spreafico Breakdown of academic impact, for papers by Yoshiki Mikami Breakdown of academic impact, for papers by Chang‐Ok Suh Breakdown of academic impact, for papers by Weining Zhen Breakdown of academic impact, for papers by Mercè Jordà Breakdown of academic impact, for papers by Christina Messiou Breakdown of academic impact, for papers by Robert A. Lefkowitz Breakdown of academic impact, for papers by Rick L. Haas Breakdown of academic impact, for papers by Noah Federman Breakdown of academic impact, for papers by Malcolm Hayes
Rankless by CCL
2026